Drug Designing: Open Access
Open Access

Abstract

CRISPR-Informed Drug Discovery: Targeting Synthetic Lethal Networks in Cancer Cells

Eleanor Grayson*

The advent of CRISPR-Cas9 genome-editing technology has profoundly transformed the landscape of drug discovery, particularly in the context of oncology. Among its most promising applications is the identification and targeting of synthetic lethal interactions gene pairs where the simultaneous loss of function leads to cell death, while the inactivation of either gene alone is tolerated. This concept has gained traction as a strategic approach to selectively target cancer cells by exploiting their specific genetic vulnerabilities without harming normal cells. CRISPR-based screening platforms allow researchers to perform large-scale, unbiased loss-of-function studies across thousands of genes in various cancer cell models, uncovering synthetic lethal partners that can be manipulated pharmacologically. These discoveries are reshaping how new cancer therapeutics are developed, ushering in an era of precision oncology where treatments are informed by the individual genetic makeup of tumors.

Published Date: 2025-03-04; Received Date: 2025-02-03